Palliative Radiotherapy for Symptomatic Locally Advanced Gastric Cancer: A Phase II Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I/II Study of Neoadjuvant Chemoradiotherapy With S-1/ Oxaliplatin in Patients With Gastric Cancer: Randomized Phase II Study of S-1/RT vs. S-1/Oxaliplatin/RT

NCT01106066

Phase I: To Determine the Maximum Tolerated Dose (MTD) Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin

TERMINATED PHASE1/PHASE2

Feasibility Study of Intraperitoneal Paclitaxel

NCT01739894

Gastric Cancer

UNKNOWN PHASE2

Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer

NCT02072317

Advanced Gastric Cancer

UNKNOWN PHASE2

A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

NCT01736410

HER 2 Positive Advanced Gastric Cancer

COMPLETED PHASE2

Paclitaxel-HDFL for Locally Advanced and Recurrent/Metastatic Gastric Cancers

NCT00154726

Locally Advanced and Recurrent/Metastatic Gastric Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The hypothesis of this study is that a radiotherapy dose of 36Gy in 12 fractions, which equates to a BED of 48.6Gy, increases the response rates of symptom relief compared to historical controls. (Tey et al.) With this dose fractionation is used for bleeding, there is an increase in response rates from 55%(historical) to 75%for pain, there is an increase in response rates from 25% (historical) to 45% for obstruction, there is an increase in response rates from 25% (historical) to 45%

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiotherapy for gastric cancer

Single arm study

Group Type EXPERIMENTAL

Palliative Radiotherapy

Intervention Type RADIATION

Palliative Radiotherapy to a total dose of 36Gy in 12 fractions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.